France news - the latest biotech news from Labiotech.eu

Home France Page 52

Latest Posts

bioplastic

News and Trends 5 Aug 2015

The Most Advanced Bioplastic Plant to Be Built in France

Bio-on and Cristal Union will work together to build the most advanced plant producing bioplastics in France. This exclusive process will transform sugar beet co-products in a 100% biodegradable plastic! Your plastic bottle will soon be produced from sugar beet! Bio-on and Cristal Union just signed an agreement to work together on the construction of […]

August 5, 2015 - 2 minutesmins - By Joachim Eeckhout

Amoéba

News and Trends 5 Aug 2015

Interview with Fabrice Plasson, Amoéba’s CEO: “We created a biocide using microorganisms”

Water treatment against pathogens has not changed since 1914 when we first discovered the use of chlorine. Industrial manufacturers are still using such chemicals to decontaminate waters involved in their process but can only destroy 0,5% of pathogens! The French company Amoéba, has discovered a way to eliminate 100% of pathogens without using any chemicals! […]

August 5, 2015 - 5 minutesmins - By Joachim Eeckhout

Erytech

News and Trends 29 Jul 2015

Erytech follows the path of DBV and Cellectis into the US stock exchange

Erytech Pharma, developer of an innovative ‘tumor starvation’ treatment, today announced that it plans to conduct a registered initial public offering in the United States and thus, plays in the major league with its French fellows DBV and Cellectis. It’s definitely the last trend in Biotech! European companies are queuing up to enter the US stock market. In […]

July 29, 2015 - 2 minutesmins - By Joachim Eeckhout

Antoine Hubert

News and Trends 28 Jul 2015

We met Antoine Hubert, CEO of Ynsect and awarded Innovator Under 35 by the MIT

Each year since 1999, MIT Technology Review, the journal from the top-rank US University, discovers new generations of Innovators Under 35. The awarded young leaders are developing new technologies to solve the major global challenges of today in remarkably different ways and impacting the lives of millions of people around the globe. We had the […]

July 28, 2015 - 7 minutesmins - By Marie Godar

astrazeneca deal genzyme rare disease

News and Trends 28 Jul 2015

Struggling AstraZeneca sells Rare Disease drug to Genzyme-Sanofi for €300M

The Pharma giant AstraZeneca is still struggling even if in better shape. It just sold one of his rare disease drug already on the market to THE rare disease Biotech Genzyme, now part of Sanofi. AstraZeneca is under pressure. Last April 2015, the company reported a fall in revenues and profits (7% lower than previous […]

July 28, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 27 Jul 2015

Hunt for Hypercholesterolemia Drug Approval: Sanofi vs Amgen vs Pfizer

Cardiovascular diseases kill around 2.6 million people each year and embody one of the biggest healthcare markets in the World. Not surprising to see Big Pharmas/Biotechs overactive in this field. What are their plans? Today, Sanofi‘s hypercholesterolemia therapy Praluent was recommended to the European market. It is a fully human monoclonal antibody developed in collaboration with the American Big Biotech Regeneron. But Amgen announced […]

July 27, 2015 - 2 minutesmins - By Philip Hemme

ADVERTISEMENT

sugar beet global bioenergies first generation biofuel

News and Trends 23 Jul 2015

Why is Global Bioenergies moving back to First-Generation Biofuels?

Second-generation biofuels have solved many problems caused by their predecessors, first-generation biofuels. The French synthetic biology company Global Bioenergies just announced that it has adapted its gaz-producing process to sucrose, a first-generation biofuel. Why would it make this step backwards? Global Bioenergies is one of the leading European industrial Biotech companies. It wants to replace fossil oil with a biosourced […]

July 23, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 22 Jul 2015

Sensorion raises an additional €8M to test its inner ear drug

Listen up! French biotech Sensorion just raised €8M through a private placement to advance its inner ear disease drug to Phase II. Since its IPO in April, the value of the company has quadrupled. Sensorion emerged in 2009 as a spin-off of Inserm, the French institute of health and medical research. It specialises in the treatment of […]

July 22, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine

HIV is definitely under the spotlight today. Just after Theravectys’ announcement about its phase I/II success, InnaVirVax completed a third funding round to accelerate its Phase 2 clinical development. The first-in-class immunotherapy designed to treat HIV infections gained further support by all the historical investors in the company. Since 1987, HIV has mainly been treated with a combination of […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

Theravectys

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

DBV raised €255M on the NASDAQ

[Update 20/07/2015] After successfully closing its Underwritten Public Offering, DBV finally raised €255M ($281,5M) on the NASDAQ. Original article from 16/07/2015: DBV Technologies is going for its second fundraising on the NASDAQ, hoping for €223M. €68.6M were already secured last week from Baker Bros. Advisors LP. The money will allow the company to stay independent all […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

sanofi genzyme

News and Trends 16 Jul 2015

Sanofi’s Extreme Makeover gives prominence to Genzyme

There seems to be a tendency towards revolution amongst Sanofi’s CEOs. Olivier Brandicourt, Managing director of the French drugmaker since his €4.1M golden handshake with the company, has come up with a restructuration plan that will reduce Sanofi’s business units from seven to five. The French businessman expects this reorganization will help the company to […]

July 16, 2015 - 2 minutesmins - By Lourdes Riquelme

ADVERTISEMENT